公开(公告)号：US20230272045A1

公开(公告)日：2023-08-31

申请号：US18001480

申请日：2021-06-11

申请人： MONASH UNIVERSITY

发明人： Mikaël MARTINO ,  Ziad JULIER

IPC分类号： C07K14/715 ,  C07K14/475 ,  C12N15/62 ,  A61P17/02 ,  C07K14/71

CPC分类号： C07K14/7155 ,  C07K14/475 ,  C12N15/62 ,  A61P17/02 ,  C07K14/71 ,  C07K2319/33

摘要： The present invention provides a fusion protein comprising interleukin-1 receptor antagonist (IL-1Ra) and an extracellular matrix (ECM) binding peptide which specifically binds to one or more or all extracellular matrix proteins selected from the group consisting of fibrinogen, fibronectin, vitronectin, tenascin C and heparan sulfate and use of the fusion protein to treat conditions in which administration of IL-1Ra is beneficial or in which IL-1R1 signalling needs to be dampened, to enhance tissue regeneration, particularly bone regeneration and/or wound repair or for treating wounds, burns and muscle, cartilage, tendon and bone disorders, to enhance the regenerative activity of growth factor administration or to reduce inflammation or desensitisation of a cell to growth factor stimulation.